← All trials
NCT02477644
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2015
- Primary completion
- Jun 1, 2022
- Completion date
- Jun 1, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 612
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- ARCAGY-GINECOLead sponsor
- Mario Negri InstituteCollaborator
- Centre Leon BerardOverall official - principal investigator
- Grupo Español de Investigación en Cáncer de OvarioCollaborator
- Nordic Society for Gynaecologic OncologyCollaborator
- Gynecologic Oncology Trial & Investigation ConsortiumCollaborator
- Katholieke Universiteit LeuvenCollaborator
- Arbeitsgemeinschaft Gynaekologische Onkologie AustriaCollaborator
- Multicenter Italian Trials in Ovarian CancerCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.